Johnson & Johnson (JNJ) reported Q4 FY 2017 earnings of $1.74 per share (versus $1.58 in Q4 FY 2016), beating analysts' consensus estimate of $1.72.
The company's quarterly revenues amounted to $20.195 bln (+11.5% y/y), generally in-line with analysts' consensus estimate of $20.080 bln.
The company also issued guidance for FY 2018, projecting EPS of $8.00-8.20 (versus analysts' consensus estimate of $7.87) and revenues of $80.6-81.4 bln (versus analysts' consensus estimate of $80.71 bln).
JNJ rose to $149.50 (+0.92%) in pre-market trading.